OneSource Specialty Pharma partners with Xbrane Biopharma for biosimilar manufacturing, aiming to strengthen global supply ...

Alvotech (NASDAQ: ALVO, ALVO-SDB), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, has completed its transaction with Xbrane ...

OneSource Specialty Pharma and Xbrane Biopharma AB, a Sweden-headquartered biotechnology company, today announced a partnership focused on the commercial manufacturing of Xbrane's biosimilar portfolio ...

Onesource Specialty Pharma advanced 1.55% to Rs 2057 after the company announced a partnership with Sweden-based Xbrane Biopharma AB for manufacturing biosimilars for global markets.

Xbrane re-submitted the BLA (Biologics License Application) for its investigational biosimilar candidate to LUCENTIS® (ranibizumab) to the FDA (US Food and Drug Administration) in December 2024.

All regulatory conditions have been fulfilled. The transaction, which was announced on March 20, 2025, and approved by Xbrane's Extraordinary General Meeting on April 14, 2025, entails a total ...

Alvotech, a global biotech firm, has successfully completed its acquisition of Xbrane Biopharma's research and development organization and a biosimilar candidate for Cimzia® (certolizumab pegol ...